Rashid Mamunur, Manivet Philippe, Nishio Hiroaki, Pratuangdejkul Jaturong, Rajab Mazen, Ishiguro Masaji, Launay Jean Marie, Nagatomo Takafumi
Department of Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, 5-13-2 Kamishinei-cho, Japan.
Life Sci. 2003 May 30;73(2):193-207. doi: 10.1016/s0024-3205(03)00227-3.
The aim of the present study was to investigate the binding sites interactions and the selectivity of sarpogrelate to human 5-HT(2) receptor family (5-HT(2A), 5-HT(2B) and 5-HT(2C) receptor subtypes) using molecular modeling. Rhodopsin (RH) crystal structures were used as template to build structural models of the human serotonin-2A and -2C receptors (5-HT(2A)R, 5-HT(2C)R), whereas for 5-HT(2B)R, we used our previously published three-dimensional (3D) models based on bacteriorhodopsin (BR). Sarpogrelate, a novel 5-HT(2)R antagonist, was docked to the receptors. Molecular dynamics (MD) simulations produced the strongest interaction for 5-HT(2A)R/sarpogrelate complex. Upon binding, sarpogrelate constraints aromatic residues network (Trp(3.28), Phe(5.47), Trp(6.48), Phe(6.51), Phe(6.52) in 5-HT(2A)R; Phe(3.35), Phe(6.51), Trp(7.40) in 5-HT(2B)R; Trp(3.28), Phe(3.35), Phe(5.47), Trp(6.48), Phe(6.51), Phe(6.52) in 5-HT(2C)R) in a stacked configuration, preventing activation of the receptor. The models suggest that the structural origin of the selectivity of sarpogrelate to 5-HT(2A)R vs both 5-HT(2B)R and 5-HT(2C)R comes from the following results: (1) The tight interaction between the antagonist and the transmembrane domain (TMD) 3. Asp(3.32) neutralizes the cationic head and interacts simultaneously with carboxylic group hydrogen of the antagonist molecule. (2) Due to steric hindrance, Ser(5.46) (vs Ala(5.46) in 5HT(2B) and 5HT(2C)) prevents sarpogrelate to enter deeply inside the hydrophobic core of the helix bundle and to interact with Pro(5.50). (3) The side chain of Ile(4.56) (vs Ile(4.56) in 5HT(2B)R and Val(4.56) in 5HT(2C)R) constraints sarpogrelate to adjust its position by translating toward the strongly attractive Asp(3.32). These results are in good agreement with binding affinities (pKi) of sarpogrelate for 5-HT(2) receptor family expressed in transfected cell.
本研究的目的是使用分子建模方法研究沙格雷酯与人5-羟色胺(5-HT)2受体家族(5-HT2A、5-HT2B和5-HT2C受体亚型)的结合位点相互作用及选择性。以视紫红质(RH)晶体结构为模板构建人血清素-2A和-2C受体(5-HT2AR、5-HT2CR)的结构模型,而对于5-HT2BR,我们使用之前基于细菌视紫红质(BR)发表的三维(3D)模型。将新型5-HT2R拮抗剂沙格雷酯对接至这些受体。分子动力学(MD)模拟显示5-HT2AR/沙格雷酯复合物的相互作用最强。结合后,沙格雷酯使芳香族残基网络(5-HT2AR中的Trp(3.28)、Phe(5.47)、Trp(6.48)、Phe(6.51)、Phe(6.52);5-HT2BR中的Phe(3.35)、Phe(6.51)、Trp(7.40);5-HT2CR中的Trp(3.28)、Phe(3.35)、Phe(5.47)、Trp(6.48)、Phe(6.51)、Phe(6.52))呈堆积构型,从而阻止受体激活。这些模型表明,沙格雷酯对5-HT2AR相对于5-HT2BR和5-HT2CR的选择性的结构根源来自以下结果:(1)拮抗剂与跨膜结构域(TMD)3之间的紧密相互作用。Asp(3.32)中和阳离子头部并同时与拮抗剂分子的羧基氢相互作用。(2)由于空间位阻,Ser(5.46)(相对于5HT2B和5HT2C中的Ala(5.46))阻止沙格雷酯深入螺旋束疏水核心内部并与Pro(5.50)相互作用。(3)Ile(4.56)的侧链(相对于5HT2BR中的Ile(4.56)和5HT2CR中的Val(4.56))使沙格雷酯通过向极具吸引力的Asp(3.32)平移来调整其位置。这些结果与沙格雷酯对转染细胞中表达的5-HT2受体家族的结合亲和力(pKi)高度一致。